NICE announced its modified publication targets (24 June 2020) for this financial year to include: 4 guideline topics with more to be added to the list in the coming weeks, 8 quality standards, up to 70 technology appraisals and highly specialised technologies guidance and up to 42 interventional procedures, diagnostics and medical technologies guidance.
As members will know, since mid-March NICE has concentrated on producing 21 rapid COVID-19 related guidelines, along with other therapeutically-critical guidance.
When deciding which guidance to publish first, NICE considered “the clinical priority of the topic, its stage of development and original planned publication date, as well as committee availability and staff capacity.”
The first of the guidelines to be published are listed below.
- Joint replacement (primary): hip, knee and shoulder (NG157) – published on 4 June 2020
- Perioperative care in adults
- Rehabilitation in adults with complex psychosis and related severe mental health conditions
- Behaviour change: digital and mobile health interventions.
- Specialist neonatal respiratory care for babies born pre-term
- Renal and ureteric stones
- Decision making and mental capacity
Guidance related to NICE’s health technology evaluation programmes:
The first guidance to publish will be:
- Fremanezumab for chronic, episodic migraine – published on 3 June 2020
- Tests to help assess risk of acute kidney injury for people being considered for critical care– published on 17 June 2020
- Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure– published today (24 June 2020)
- Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia– published today (24 June 2020)
- Artificial iris insertion for acquired aniridia (expected publication date: 22 July 2020)
- Artificial iris insertion for congenital aniridia (expected publication date: 22 July 2020)
Further guidance will follow, and once confirmed, new expected publication dates will be added to specific topic pages on the NICE website. NICE’s guidance centres and developers will communicate directly with committees and registered stakeholders to notify them of any likely impact on specific guidance topics.